NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Reviewed May 26, 2026

GHRP-2

Peptide ·Insufficient evidence ·Reviewed May 2026

GHRP-2, also called pralmorelin, is a synthetic hexapeptide ghrelin receptor agonist that stimulates growth hormone release. It is approved in Japan for diagnostic assessment of growth hormone deficiency, but it is not FDA-approved for human use in the United States and is not approved for anti-aging, bodybuilding, fat loss, or wellness protocols. Long-term therapeutic evidence is limited, and risks include appetite change, glucose effects, cortisol or prolactin elevations, edema, and WADA-prohibited status.

What it's good for
  • Acutely stimulates GH release in diagnostic or research settings1,2
  • Approved in Japan for GH deficiency diagnostic testing2
  • May increase appetite
  • No approved US wellness use
What to watch for
  • Hunger
  • Flushing
  • Headache
  • Active malignancy
  • Pregnancy and breastfeeding

The bottom line

Evidence rating insufficient. Most-documented uses: acutely stimulates gh release in diagnostic or research settings, approved in japan for gh deficiency diagnostic testing, may increase appetite. 3 sources indexed (1998–2005), with 3 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

GHRP-2 activates GHS-R1a receptors in the pituitary and hypothalamus to stimulate GH pulses through a pathway distinct from GHRH. It can also influence ACTH, cortisol, prolactin, appetite, and gastric signaling because the ghrelin receptor is not restricted to somatotrophs. Repeated dosing may attenuate GH response, and acute hormone elevation does not prove durable clinical benefit.3,1

Class
Synthetic GH secretagogue and diagnostic pralmorelin peptide
Found in food
None
Low-status signs
No GHRP-2 deficiency exists
Dosing

Dosing & protocol.

Common range
No FDA-approved human dose; Japan diagnostic use is clinic-administered and protocol-specific
Recommended form
Not recommended as a supplement; use only as approved diagnostic drug where legally available or in approved research

Peptide use in studies is parenteral. Nonsterile or research-grade injection is unsafe.

Forms

Forms & what to buy.

Ranked by evidence and value.

Pralmorelin Diagnostic Injection Recommended
Approved only in specific jurisdictions for diagnostic testing. Clinic-administered parenteral use.
PremiumDiagnostic protocol only
Lyophilized Research Peptide
Not FDA-approved and not appropriate for human injection. Sterility and identity cannot be assumed.
PremiumNo human supplement dose
Cost

What it actually costs.

Real-world pricing across three quality tiers. Assumes Research peptide vial.

BudgetBest value
$45 /mo
$1.50 per dose
Mid
$135 /mo
$4.50 per dose
Premium
$360 /mo
$12.00 per dose

Research-market pricing is not a recommendation for human use. Updated 2026-06-04.

Goals

Goal-based dosing.

GH Deficiency Diagnostic Testing

Dose: Jurisdiction-specific diagnostic protocol2

Timing: Endocrinology clinic protocol

Not a treatment or wellness dose.

Body Composition or Anti-Aging

Dose: No FDA-approved dose

Timing: Not applicable

Long-term outcome evidence is inadequate and use is prohibited in sport.

Appetite Stimulation

Dose: No approved US dose

Timing: Not applicable

Hunger is a pharmacologic effect and may worsen metabolic risk.

Lab work

Markers to track.

What to test, the optimal window inside the conventional range, and how long a response takes.

Insulin-Like Growth Factor 1 IGF-1

May or may not increase with repeated use; short studies show possible response attenuation.3,1

Optimal
80–250 ng/mL
Conventional
50–300 ng/mL
Responds in
4-8 weeks if medically monitored

Do not use for unsupervised research peptide decisions.

Fasting glucoseHbA1cProlactin

Prolactin

May increase acutely with some GHRP-class secretagogues.1,2

Optimal
5–20 ng/mL
Conventional
4–25 ng/mL
Responds in
As clinically indicated

Evaluate persistent elevations for pituitary or medication causes.

IGF-1TSHTestosterone
Why people use it

Symptoms it's matched to.

Where this appears in the symptom-to-supplement map, ranked by relevance.

Low appetite

20% relevance

Ghrelin receptor activation can increase food intake acutely.1

DigestiveInsufficient evidenceNot recommended

Not an approved appetite medication in the US.

Low IGF-1 on labs

18% relevance

Acutely stimulates GH, but repeated short exposure may not raise IGF-1.3,1

HormoneInsufficient evidenceNot recommended outside medical testing

Endocrinology evaluation is required.

Poor muscle recovery

8% relevance

Performance claims are extrapolated from GH pulses, not proven outcomes.

AthleticInsufficient evidenceNot recommended

WADA-prohibited.

Safety

Full safety detail.

Side effects

  • Hunger
  • Flushing
  • Headache
  • Sleepiness
  • Injection-site reaction
  • Water retention
  • Glucose intolerance
  • Possible cortisol or prolactin elevation

Contraindications

  • Active malignancy
  • Pregnancy and breastfeeding
  • Diabetes or uncontrolled glucose intolerance without specialist care
  • Pituitary disease without endocrinology supervision
  • Competitive athletes subject to anti-doping rules
  • Non-FDA-approved wellness or performance use
  • Research-grade peptide injection3,1
Interactions

Interaction records.

ModerateCaution

Berberine

Berberine may lower glucose while GHRP-2 can affect glucose and appetite.

Recommendation: Avoid unsupervised stacking; monitor glucose if a clinician is supervising endocrine testing.

ModerateCaution

Alpha-Lipoic Acid

Alpha-lipoic acid affects insulin sensitivity while GHRP-2 may alter glucose handling.

Recommendation: Use glucose monitoring in any supervised context and avoid research-product self-use.

InfoCaution

Creatine

Creatine water weight can obscure edema or rapid weight changes from GH secretagogue use.

Recommendation: Track edema symptoms, blood pressure, and glucose rather than interpreting scale weight alone.

Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Randomized controlled trials

1
  • 1Growth Hormone Releasing Peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy menNeeds sourceNo linkLaferrere B et al. · Journal of Clinical Endocrinology and Metabolism · 2005

    GHRP-2 infusion increased ad libitum food intake in a small study of healthy men.

Reviews & position papers

1
  • 2Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LNNeeds sourceNo linkNo authors listed · Drugs in R&D · 2004

    Review summarized pralmorelin development and clinical diagnostic context.

Reference material

1
  • 3A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young menNeeds sourceNo linkJanssen JA et al. · Clinical Endocrinology · 1998

    Daily GHRP-2 caused attenuation of GH response and did not raise IGF-1 over 5 days.

Keep exploring

Deep dives & adjacent profiles.

This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.

Use this with your stack

GHRP-2 in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.